Literature DB >> 19472011

When is prophylactic thyroidectomy indicated for patients with the RET codon 609 mutation?

Daniel Calva1, Thomas M O'Dorisio, M Sue O'Dorisio, Geeta Lal, Sonia Sugg, Ronald J Weigel, James R Howe.   

Abstract

BACKGROUND: Mutations in the RET proto-oncogene cause multiple endocrine neoplasia type 2A (MEN2A), and prophylactic thyroidectomy has generally been recommended before the age of 5 years. Patients with codon 609 mutations develop MTC at a later age and therefore the timing of prophylactic thyroidectomy is less clear. We report a three-generation family with C609Y RET mutation where members having prophylactic or therapeutic thyroidectomy call the current recommendations for age at thyroidectomy into question.
METHODS: Sixteen family members underwent thyroidectomy, for which clinical, laboratory, and pathological data were analyzed. A literature review of RET codon 609 mutations was carried out.
RESULTS: Data were collected from 16 patients from this 38-member kindred. None of these affected members had pheochromocytoma, and one had a parathyroid adenoma. Nine of 16 patients had MTC (mean age 44.7 years, range 29-59 years) and elevated basal calcitonin levels; 6 of these 9 had lymph node metastases. Two patients had C-cell hyperplasia (CCH) at ages 18 and 37 years, and five patients had normal thyroid pathology (mean age 16 years, range 5-37 years). In the literature, a family with C609Y mutation was reported, with 15 members having MTC (mean age 42 years, range 21-59 years), and 6 with CCH (mean age 24 years, range 15-37 years).
CONCLUSION: The youngest patient with C609Y RET mutation and MTC was 21 years old, and the youngest patient with CCH was 15 years old at diagnosis. These data suggest that patients with RET C609Y mutations can delay thyroidectomy until 10-15 years of age, with annual calcitonin screening prior to thyroidectomy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19472011     DOI: 10.1245/s10434-009-0524-3

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  10 in total

Review 1.  Familial pediatric endocrine tumors.

Authors:  Sarinda Millar; Lisa Bradley; Deirdre E Donnelly; Dennis Carson; Patrick J Morrison
Journal:  Oncologist       Date:  2011-09-20

Review 2.  Translational research in endocrine surgery.

Authors:  Scott K Sherman; James R Howe
Journal:  Surg Oncol Clin N Am       Date:  2013-07-26       Impact factor: 3.495

Review 3.  Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.

Authors:  Samuel A Wells; Sylvia L Asa; Henning Dralle; Rossella Elisei; Douglas B Evans; Robert F Gagel; Nancy Lee; Andreas Machens; Jeffrey F Moley; Furio Pacini; Friedhelm Raue; Karin Frank-Raue; Bruce Robinson; M Sara Rosenthal; Massimo Santoro; Martin Schlumberger; Manisha Shah; Steven G Waguespack
Journal:  Thyroid       Date:  2015-06       Impact factor: 6.568

4.  Prevalence by age and predictors of medullary thyroid cancer in patients with lower risk germline RET proto-oncogene mutations.

Authors:  Thereasa A Rich; Lei Feng; Naifa Busaidy; Gilbert J Cote; Robert F Gagel; Mimi Hu; Camilo Jimenez; Jeffrey E Lee; Nancy Perrier; Steven I Sherman; Steven G Waguespack; Anita Ying; Elizabeth Grubbs
Journal:  Thyroid       Date:  2014-06-06       Impact factor: 6.568

Review 5.  Hereditary medullary thyroid carcinoma: the management dilemma.

Authors:  Ping Zhou; Jian Liu; Shao-Wen Cheng; Bing Wang; Rong Yang; Ling Peng
Journal:  Fam Cancer       Date:  2012-06       Impact factor: 2.375

Review 6.  Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an update.

Authors:  Samuel A Wells; Furio Pacini; Bruce G Robinson; Massimo Santoro
Journal:  J Clin Endocrinol Metab       Date:  2013-06-06       Impact factor: 5.958

7.  Pediatric Medullary Thyroid Carcinoma.

Authors:  Dmytro Starenki; Jong-In Park
Journal:  J Pediatr Oncol       Date:  2015

8.  Disease-modifying polymorphisms and C609Y mutation of RET associated with high penetrance of phaeochromocytoma and low rate of MTC in MEN2A.

Authors:  Rowena Speak; Jackie Cook; Barney Harrison; John Newell-Price
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2016-11-25

9.  Genomic sequencing identifies secondary findings in a cohort of parent study participants.

Authors:  Michelle L Thompson; Candice R Finnila; Kevin M Bowling; Kyle B Brothers; Matthew B Neu; Michelle D Amaral; Susan M Hiatt; Kelly M East; David E Gray; James M J Lawlor; Whitley V Kelley; Edward J Lose; Carla A Rich; Shirley Simmons; Shawn E Levy; Richard M Myers; Gregory S Barsh; E Martina Bebin; Gregory M Cooper
Journal:  Genet Med       Date:  2018-04-12       Impact factor: 8.822

Review 10.  RET codon 609 mutations: a contribution for better clinical managing.

Authors:  Caterina Mian; Paola Sartorato; Susi Barollo; Mariangela Zane; Giuseppe Opocher
Journal:  Clinics (Sao Paulo)       Date:  2012       Impact factor: 2.365

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.